Stay updated with breaking news from Ulrich Dauer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
24.04.2024 - Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date ...
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including
EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut...
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023 ...
Investegate announcements from Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer